Eye Opener: Gunman on the run after deadly Tenn. shooting

FAN Editor
CBSN

<![CDATA[
article.article .article-lead-image { background-size: cover; background-position: unset; background-repeat: no-repeat; height: 500px; box-shadow: 0 100px 100px rgba(0,0,0,0.05); margin-bottom: 30px; display: block !important;}
.evening-news .module-rem h2.title,
.evening-news .module>.title,
.evening-news .listing-full-focus-with-label .items .item>.label,
.evening-news .listing-full-lead-media .items .item>.label,
.evening-news .module-listing.module-basic .module-heading.title,
.evening-news .module .module-heading.title { font-family: “futura-pt”,Helvetica,Roboto,sans-serif;
}
.mobile [data-role=”content”] > .container::before { display: none;
} ]]]]>
]]>
<![CDATA[

]]>
<![CDATA[

]]>
<![CDATA[

]]>

Free America Network Articles

Leave a Reply

Next Post

Goldman upgrades Merck, calls it one of the firm's favorite stocks because of Keytruda lung cancer breakthrough

Goldman Sachs upgraded shares of Merck to buy from neutral and named it to its Americas Conviction List of favorite stocks on Monday because of potential booming sales from the drugmaker’s blockbuster lung cancer treatment Keytruda. “We believe the narrative for this company is quickly changing with the success of […]

You May Like